Cellectis S.A. (NASDAQ:CLLS) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET
Company Participants
Arthur Stril - CFO and Chief Business Officer
Andre Choulika - CEO
Adrian Kilcoyne - CMO
Conference Call Participants
Gena Wang - Barclays
Jack Allen - Baird
Sebastiaan van der Schoot - Kempen
Silvan Tuerkcan - Citizens
Jack Allen - Baird
Hangfei Fu - Jefferies
Operator
Good day, everyone, and welcome to today's Cellectis Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note, today's conference is being recorded. [Operator Instructions]
It is now my pleasure to turn the conference over to Arthur Stril. Please go ahead.
Arthur Stril
Good morning, and welcome, everyone, to Cellectis fourth quarter and full year 2024 business update and financial results conference call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer; and Dr. Adrian Kilcoyne, our Chief Medical Officer.
Yesterday evening, Cellectis issued a 6-K and press release reporting our financial statements for the 12-months period ended December 31, 2024, and a business updates. The report and press release are available on our website at cellectis.com.
As a reminder, we will make statements regarding Cellectis financial outlook, including the sufficiency of cash to fund operations in addition to our manufacturing, regulatory and product development status as well as product development status of our license partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our license partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange
- Read more current CLLS analysis and news
- View all earnings call transcripts